-

Bristol Myers Squibb Announces Dividend

NEW YORK--(BUSINESS WIRE)--Bristol Myers Squibb (NYSE: BMY) today announced that its Board of Directors has declared a quarterly dividend of forty-nine cents ($0.49) per share on the $.10 par value common stock of the company. The dividend is payable on November 1, 2021 to stockholders of record at the close of business on October 1, 2021.

In addition, the Board of Directors has declared a quarterly dividend of fifty cents ($0.50) per share on the company’s $2.00 convertible preferred stock, payable December 1, 2021 to stockholders of record at the close of business on November 9, 2021.

About Bristol Myers Squibb Company

Bristol Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop, and deliver innovative medicines that help patients prevail over serious diseases. For more information about Bristol Myers Squibb, visit us at BMS.com or follow us on LinkedIn, Twitter, YouTube, Facebook, and Instagram.

corporatefinancial-news

Contacts

Media:
media@bms.com

Investors:
Nina Goworek, 908-673-9711, nina.goworek@bms.com
Karen Wheeler, 609-252-3396, karen.wheeler@bms.com

Bristol Myers Squibb

NYSE:BMY

Release Summary
Bristol Myers Squibb Announces Dividend
Release Versions
$Cashtags

Contacts

Media:
media@bms.com

Investors:
Nina Goworek, 908-673-9711, nina.goworek@bms.com
Karen Wheeler, 609-252-3396, karen.wheeler@bms.com

More News From Bristol Myers Squibb

Bristol Myers Squibb to Participate in the TD Cowen 46th Annual Health Care Conference

PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb to Participate in the TD Cowen 46th Annual Health Care Conference...

Bristol Myers Squibb Announces Positive Top-Line Results from Registrational Phase 2 Study of Luspatercept in Adults with Alpha (α)-Thalassemia

PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb Announces Positive Top-Line Results from Registrational Phase 2 Study of Luspatercept in Adults with Alpha (α)-Thalassemia...

U.S. Food and Drug Administration Accepts Bristol Myers Squibb's New Drug Application for Iberdomide in Patients with Relapsed or Refractory Multiple Myeloma

PRINCETON, N.J.--(BUSINESS WIRE)--U.S. Food and Drug Administration Accepts Bristol Myers Squibb's New Drug Application for Iberdomide in Relapsed or Refractory Multiple Myeloma...
Back to Newsroom